Ampliphi Biosciences Corp (NYSEAMERICAN:APHB – Get Free Report)’s stock price fell 1.2% during mid-day trading on Friday. The stock traded as low as $3.15 and last traded at $3.25. 102,950 shares traded hands during trading, a decline of 88% from the average daily volume of 842,200 shares. The stock had previously closed at $3.29.
Ampliphi Biosciences Trading Up 0.9%
The stock’s 50-day moving average price is $4.21 and its 200 day moving average price is $6.97.
Ampliphi Biosciences Company Profile
AmpliPhi Biosciences Corporation was a clinical-stage biotechnology company focused on developing bacteriophage therapies for bacterial infections, particularly infections caused by antibiotic-resistant pathogens. Bacteriophages are naturally occurring viruses that selectively infect and destroy bacteria, offering a potential alternative or complement to conventional antibiotics.
The company developed a proprietary phage-discovery and development platform and advanced product candidates including AP-PA01, an investigational therapy targeting Pseudomonas aeruginosa infections, and AP-SA02, which targeted Staphylococcus aureus.
Read More
- Five stocks we like better than Ampliphi Biosciences
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Ampliphi Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampliphi Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
